Screever, Elles M.
van der Wal, Martje H. L.
van Veldhuisen, Dirk J.
Jaarsma, Tiny
Koops, Astrid
van Dijk, Kuna S.
Warink-Riemersma, Janke
Coster, Jenifer E.
Westenbrink, B. Daan
van der Meer, Peter
de Boer, Rudolf A.
Meijers, Wouter C.
Funding for this research was provided by:
Hartstichting (CVON SHE-PREDICTS-HF, grant 2017-21, CVON RED-CVD, grant 2017-11, CVON PREDICT2, grant 2018-30, CVON DOUBLE DOSE, grant 2020B005, grant 2000Z003, Dekker grant 03-005-2021-T005)
Fondation Leducq (Cure PhosphoLambaN induced Cardiomyopathy (Cure-PLaN))
H2020 European Research Council (ERC CoG 818715, SECRETE-HF)
Universitair Medisch Centrum Groningen (Mandema-Stipendium of the Junior Scientific Masterclass 2020-10)
Article History
Received: 11 May 2022
Accepted: 27 July 2022
First Online: 17 August 2022
Declarations
:
: The UMCG, which employs several of the authors has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals Gmbh, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche. Dr. de Boer received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche. All other authors report no disclosures.